演講嘉賓

香港科學院院⼠，英國皇家外科醫學院院⼠，英國愛丁堡皇家外科醫學院院⼠，英國格拉斯哥皇家醫學院外科院⼠，愛爾蘭皇家外科醫學院院⼠，國皇家兒科醫學院榮授院⼠，美國外科協會榮授院⼠現任澳門科技⼤學副校長。2015-2019 年擔任香港⼤學首席副校長，香港⼤學名譽教授及榮譽臨床教授。為⼀名蜚聲國際的外科醫⽣、科學家及⼤學領導。譚教授致⼒研究及發展小兒微創⼿術及先天性巨⼤結腸癥等先天缺陷的基因及再⽣治療,在理解膽道閉鎖的疾病機制⽅面取得了空前突破,為治療這些難治性小兒胃腸道疾病在個性化醫療和再⽣醫學層面上奠定了紮實的基礎。發表 505 篇研究論⽂，其研究共獲得 35314 次引用，H 指數 66。譚教授獲頒 Denis Browne ⾦獎,是英國小兒外科醫師協會的最⾼榮譽獎項。於 2020 年獲歐洲小兒外科醫師協會頒授 RehbeinMedal 卓越成就獎,是亞洲首位獲此殊榮的小兒外科教授。

Dr. Jie TAO, PhD is a Principal Reserve Candidate for Shanghai Key Discipline of Traditional Chinese Medicine (TCM). He/She also serves as a Committee Member of the Sensory and Motor Division at the Chinese Society for Neuroscience and a Youth Committee Member of the Encephalopathy Branch at the China Association of Chinese Medicine. His/Her primary research focuses on the mechanisms of refractory epilepsy and personalized treatment strategies. Dr. Jie TAO, PhD has been honored with multiple prestigious awards, including selection into the China Association of Chinese Medicine Youth Talent Support Program, Shanghai Oriental Talents Youth Program, “Medical Rising Star” Outstanding Young Medical Talent Award, “Silver Snake Award” Nomination (Shanghai Health System), and the “Silver Snake Award – Hengjie Special Support Program.” With an outstanding academic record, Dr. Jie TAO, PhD has published 37 SCI-indexed papers as first, co-first, or corresponding author in renowned journals such as Journal of Hepatology (J Hepatol) , British Journal of Pharmacology (BJP) , Journal of Medicinal Chemistry (JMC) , and Acta Pharmacologica Sinica (APS) . He/She has also:
• Received the Second Prize of Shanghai TCM Science and Technology
Award (as first completer)
• Authored/co-authored 7 books
• Filed 12 national invention patents (2 granted)
• Led 4 National Natural Science Foundation of China (NSFC) projects
• Participated in 2 sub-projects of the National “973” Program and 1 key
project of the National Key R&D Program

Prof. Tse Hung-Fat, MBBS, MD, PhD, FACC, FRCP, FESC Prof. Hung-Fat Tse is Chair Professor of Cardiovascular Medicine, and William MW Mong Professor in Cardiology; Chairpersons and Chief of Service of the Department of Medicine; Chief in the Cardiology Division, Department of Medicine, Queen Mary Hospital; Co director, Cardiac & Vascular Center, The University of Hong Kong – Shenzhen Hospital. He is also the academic lead, HKUMed Laboratory of Cellular Therapeutics, The University of Hong Kong. He is a clinician scientist and an international expert in cardiovascular medicine, including cardiac pacing, clinical electrophysiology, and cardiovascular regeneration. Prof. Tse is one of the pioneers for novel therapies, including stem cell and devices for treatment of cardiovascular diseases. He has established the large animal laboratory for cardiovascular research as well the “Good Manufacturing Practice” laboratory for human stem cells and biological therapies in the University of Hong Kong. He has been awarded multiple major local grants (including the Theme Based Research Grant, Research Impact Fund and Innohealth) as well as national research grants (National Natural Science Foundation of China and 973 grants) for his researches. He has been participated into many international and regional clinical trials and studies, and is currently the Associate Editors for several international journals, including Cardiovascular Diabetology, Frontier in Cardiovascular Medicine, Journal of Cardiovascular Electrophysiology, Pacing and Clinical Electrophysiology and Journal of Arrhythmia. He has published over 730 scientific publications in international top-ranking scientific journals, including New England Journal of Medicine, Lancet, Nature Medicine, Nature Cell Biology, Nature Genetic, Nature Protocol, Nature Communication, Nature Biomedical Engineering, Nature Disease Primer, Cell Stem Cell, Circulation, Journal of American College of Cardiology, and European Heart Journal.

Dr. Wang earned his Master’s degree in Anesthesiology and PhD in Pharmacology from Hebei Medical University. He has held several key academic and administrative positions, including Deputy Director of the Department of Anesthesiology at Hebei University Affiliated Hospital, Director of the Research Office, and Vice Dean of the School of Medicine at Hebei University. Currently, Dr. Wang serves as a member of the Anesthesiology Teaching Subcommittee under the National Teaching Advisory Board for Higher Education Institutions of the Ministry of Education, China. He is also a committee member of the Anesthesiology Branch of the Hebei Medical Association and a corresponding editorial board member of the Chinese Journal of Anesthesiology .

Wang Yu is the chairman of the China Foundation for Hepatitis Prevention and Control. He received his M.D. from Beijing Medical University and Ph.D. from Japan Jichi Medical University. He has a professional background in viral molecular biology and immunology and has been engaged in research on hepatitis viruses and related diseases. He has successively served as the Director of the Hepatology Institute of Beijing Medical University, the Vice President of Beijing Medical University, the Deputy Director of the China National Biotechnology Development Center, and the Deputy Director of the Department of Rural and Social Development of the Ministry of Science and Technology. From 2004 to 2017, he served as the director General of the Chinese Center for Disease Control and Prevention. He is currently an executive director of the Chinese Medical Association, a member of the Expert Advisory Committee of the National Immunization Program, and a member of the World Health Organization’s Western Pacific Region Polio Eradication Certification Committee.

Dr. Haisheng Zhang is the Founder and CEO of Signet Therapeutics, and currently serves as Director of the Cancer Targeted Therapy Center at Tsinghua Shenzhen Institute and a dual-appointed professor at Nanfang Hospital, Southern Medical University. He completed postdoctoral research at Harvard Medical School’s Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
Dr. Zhang has long focused on targeted therapy and companion diagnostics for gastric
cancer, publishing over ten papers in top journals such as Cancer Discovery and Gut,
and was the first to identify a key target for diffuse gastric cancer.
In 2020, he founded Signet Therapeutics, the first company to integrate organoids and AI for innovative cancer drug discovery. The company’s lead drug, SIGX1094, is the world’s first targeted therapy for diffuse gastric cancer and is currently in Phase I trials at Peking University Cancer Hospital. It has received FDA Orphan Drug and Fast Track designations.
Dr. Zhang has been honored as a “Top Emerging Entrepreneur” in Shenzhen’s Ten Outstanding Young Entrepreneurs and listed in 36Kr’s “36 Under 36 Entrepreneurs.”

Dr. Jiayi Zhang received her B. Sc. Degree from Hong Kong Baptist University and Ph.D. degree from Brown University. She was a Brown-Coxe postdoctoral fellow in Yale University and joined Institutes of Brain Science at Fudan University in 2012. Her recent work focused on the decoding and restoration of vision. Her work was published in journals including Science, Nature Biomedical Engineering, Neuron and Nature Communications （ 3 ） . She received the State Science and Technology Advancement Award in 2023 and the Young Innovative Woman Award in Shanghai in 2020. She serves as the Vice chairman of the Neurotechnology Panel, Chinese Neuroscience Society (CNS). She is on the editorial board of Progress in Retina and Eye Research. She is currently the vice director of State Key Laboratory for Medical Neurobiology and the vice dean of Institute for Medical and Engineering Innovation at Fudan Affiliated Eye & ENT Hospital.

Professor Ning Zhang is a distinguished scientist and National Distinguished Young Scholar (recipient of the National Science Fund for Distinguished Young Scholars). He has been honored with several prestigious national awards, including selection into the National “Ten Thousand Talents Plan”, the Mid-aged and Young Leading Scientists, Engineers and Innovators Program (Ministry of Science and Technology), and the National Hundred, Thousand, and Ten Thousand Talents Project (Ministry of Human Resources). He is also a recipient of the Outstanding Contribution Expert Award and the Lee Foundation Award for Distinguished Achievement. Currently, Professor Zhang holds multiple leadership roles:

• Director, Cancer Translational Research Center, Peking University First Hospital
• Deputy Director, Peking University-Baiyao International Medical Center
• Vice President, Peking University International Cancer Institute
• Vice President, Peking University National Institute of Health Data Science
• Executive Council Member & Secretary-General, Chinese Anti-Cancer
  Association
• Chair, Translational Medicine Branch, Chinese Society of Gerontology and
  Geriatrics
• Executive Associate Editor-in-Chief, Cancer Biology & Medicine
• Executive Associate Editor-in-Chief, Medical Review
• Chief Scientist, Baiyao Group
  Professor Zhang’s research focuses on biomedical sciences, with groundbreaking work published in top-tier journals such as Nature , Cancer Cell , Nature Biotechnology , Gastroenterology , and Nature Communications .

Dr. Grace Zhou holds a Ph.D. from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences. She is a recipient of China’s National Thousand Talents Plan award, was named one of China’s Top 10 Outstanding Innovative Women (2024), and is the sole winner of the 2019 International “Antiviral Women Scientist Award”. Additionally, she was honored as one of China’s Top 10 Outstanding Female Entrepreneurs (2021), “Scientific Chinese of the Year” (2017), and a recipient of the “State Council Special Allowance” (1998). Formerly an Associate Professor in the Department of Microbiology at the University of Chicago (1999–2014),Dr. Zhou dedicated 15 years to herpesvirus research and has nearly 30 years of expertise in antiviral infection and oncolytic herpesvirus-based tumor immunotherapy. In 2015, Dr. Zhou founded ImmVira Pharma, which has since established the proprietary OVPENS platform—a fully integrated system combining scientific rationale, R&D technology, and manufacturing processes. Building on this foundation, the company has developed two key platforms: Oncolytic Virus Immunotherapy and Engineered Exosome Delivery. Oncolytic Virus Pipelines focus on multiple solid tumors with various routes of administration (intratumoral, intravenous, and intravesical). Exosome Delivery Pipelines targeting applications in large health markets, including complex metabolic, immune, respiratory, ocular, and dermatological diseases.

Extensive leadership experience in government departments and China’s top-tier tertiary hospitals. Co-editor-in-chief of Digital Health Management: Theory and Practice and Food Studies (textbook for primary and secondary school students). Deep expertise in lifelong health management and the grand health industry. Published numerous articles in authoritative media outlets, including Xinhua News Agency, People’s Daily Online, China.org.cn, Toutiao, and Phoenix News.